The liverpool adverse events profile: Relation to AED use and mood

Epilepsia

Volumn 48, Issue 3, 2007, Pages 456-463

  Panelli, Rosemary June ^a   Kilpatrick, Christine ^b   Moore, Susan M ^a   Matkovic, Zelko ^b   D'Souza, Wendyl J ^c   O'Brien, Terence J ^d  

^a SWINBURNE UNIVERSITY OF TECHNOLOGY   (Australia)

^b ROYAL MELBOURNE HOSPITAL   (Australia)

^c ALFRED HOSPITAL   (Australia)

^d UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Adverse effects; Antiepileptic drugs; Anxiety; Depression

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; LAMOTRIGINE; PHENYTOIN; VALPROIC ACID;

ABDOMINAL DISCOMFORT; AGGRESSION; ANXIETY DISORDER; ARTICLE; BLURRED VISION; DEPRESSION; DIZZINESS; DRUG INDUCED HEADACHE; DRUG MONITORING; DRUG USE; FATIGUE; HAIR LOSS; HOSPITAL ANXIETY AND DEPRESSION SCALE; HUMAN; MEDICAL ASSESSMENT; MEMORY DISORDER; MENTAL CONCENTRATION; MOUTH DISEASE; MULTIPLE REGRESSION; MULTIVARIATE ANALYSIS OF VARIANCE; NERVOUSNESS; PATIENT CODING; PATIENT MONITORING; PREDICTION; PRIORITY JOURNAL; RESTLESSNESS; SCORING SYSTEM; SEIZURE; SIDE EFFECT; SKIN DISEASE; SLEEP DISORDER; SOMNOLENCE; TREMOR; UNSTEADINESS; WEIGHT GAIN;

ADULT; ANTICONVULSANTS; ANXIETY DISORDERS; ATTITUDE TO HEALTH; AUSTRALIA; COMORBIDITY; DEPRESSIVE DISORDER; EPILEPSY; FEMALE; HEALTH STATUS; HUMANS; MALE; MULTIVARIATE ANALYSIS; PERSONALITY INVENTORY; PSYCHIATRIC STATUS RATING SCALES; PSYCHOMETRICS; QUESTIONNAIRES; REGRESSION ANALYSIS; SEIZURES;

EID: 33847613559     PISSN: 00139580     EISSN: 15281167     Source Type: Journal    
DOI: 10.1111/j.1528-1167.2006.00956.x     Document Type: Article

References (36)

1. Abetz L, Jacoby A, Baker GA, McNulty P. (2000) Patient-based assessments of quality of life in newly diagnosed epilepsy patients: validation of the NEWQOL. Epilepsia 41:1119-1128.
2. Australian Bureau of Statistics. Mental health and wellbeing: profile of adults, 1997. Cat. no. 4326.0, viewed 23 June (2006), http://www.abs.gov.au/ AUSSTATS/abs@.nsf/ProductsbyCatalogue/3F8-A5DFCBECAD9C0CA2568A900139380? OpenDocument〉.
3. Baker GA, Francis P, Middleton A, Jacoby A, Dafalla B, Young C, Smith D, Chadwick D. (1993) Development of a patient-based symptom check list to quantify adverse events in persons receiving antiepileptic drugs. Epilepsia 34(suppl 6):18 [abstract].
4. Baker GA, Middleton A, Jacoby A, Defalla B, Young C, Smith DF, Chadwick D. (1994) Initial development, reliability, and validity of a patient-based adverse event scale. Epilepsia 35(suppl 7):80 [abstract].
5. Baker GA, Jacoby A, Francis P, Chadwick DW. (1995) The Liverpool Adverse Events Drug Profile. Epilepsia 36(suppl 3):59 [abstract].
6. Baker GA, Jacoby A, Buck D, Stalgis C, Monnet D. (1997) Quality of life of people with epilepsy: a European study. Epilepsia 38:353-362.
7. Baker GA, Camfield C, Camfield P, Cramer JA, Elger CE, Johnson AL, Martins da Silva A, Meinardi H, Munari C, Perucca E, Thorbecke R. (1998) Commission on Outcome Measurement in Epilepsy, 1994-1997: final report. Epilepsia 39:213-231.
8. Baker GA. (1998) Quality of life and epilepsy: the Liverpool experience. Clinical Therapeutics 20(suppl A):A2-A12.
9. Baker GA, Jacoby A, Buck D, Brooks J, Potts P, Chadwick DW. (2001) The quality of life of older people with epilepsy: findings from a UK community study. Seizure 10:92-99.
10. Beghi E. (2004) Efficacy and tolerability of the new antiepileptic drugs: comparison of two recent guidelines. Lancet Neurology 3:618-621.
11. Brodie MJ, Dichter MA. (1997) Established antiepileptic drugs. Seizure 6:159-174.
12. Brodie MJ. (2003) Building new understandings in epilepsy: maximizing patient outcomes without sacrificing seizure control. Epilepsia 44(suppl 4):1-2.
13. Commission on Classification and Terminology of the International League Against Epilepsy. (1989) Proposal for revised classification of epilepsies and epileptic syndromes. Epilepsia 30:389-399.
14. Cramer JA, Fisher R, Ben-Menachem E, French J, Mattson RH. (1999) New antiepileptic drugs: comparison of key clinical trials. Epilepsia 40:590-600.
15. Deckers CL, Hekster YA, Keyser A, Lammers MW, Meinardi H, Renier WO. (1997) Adverse effects in epilepsy therapy. wait and see or go for it? Acta Neurologica Scandinavica 95:248-252.
16. Devinsky O, Vickrey BG, Cramer J, Perrine K, Hermann B, Meador K, Hays RD. (1995) Development of the quality of life in epilepsy inventory. Epilepsia 36:1089-1104.
17. Devinsky O, Cramer J. (2000) Safety and efficacy of standard and new antiepileptic drugs. Neurology 55(suppl 3):S5-S10.
18. Gilliam FG, Fessler AJ, Baker G, Vahle V, Carter J, Attarian H. (2004) Systematic screening allows reduction of adverse antiepileptic drug effects: a randomized trial. Neurology 62:23-27.
19. Greenwood RS. (2000) Adverse effects of antiepileptic drugs. Epilepsia 41(suppl 2):S42-S52.
20. Hermann B, Whitman S. (1992) Psychopathology in epilepsy: the role of psychology in altering paradigms of research, treatment, and prevention. American Psychologist 47:1134-1138.
21. Herrmann C. (1997) International experiences with the hospital anxiety and depression scale: a review of validation data and clinical results. Journal of Psychosomatic Research 42:17-41.
22. Hesdorffer DC, Hauser WA, Annegers JF, Cascino G. (2000) Major depression is a risk factor for seizures in older adults. Annals of Neurology 47:246-249.
23. Hesdorffer DC, Hauser WA, Olafsson E, Ludvigsson P, Kjartansson O. (2006) Depression and suicide attempt as risk factors for incident uprovoked seizure and epilepsy. Annals of Neurology 59:35-41.
24. Jacoby A, Baker GA, Steen N, Buck D. (1999) The SF-36 as a health status measure for epilepsy: a psychometric assessment. Quality of Life Research 8:351-364.
25. Kwan P, Brodie M. (2000) Early identification of refractory epilepsy. New England Journal of Medicine 342:314-319.
26. Marson AG, Kadir ZA, Chadwick DW. (1996) New antiepileptic drugs: a systematic review of their efficacy and tolerability. British Medical Journal 313:1169-1174.
27. Mattson RH, Cramer JA, Collins JF, Smith DB, Delgado-Escueta AV, Browne TR, Williamson PD, Treiman DM, McNamara JO, McCutchen CB, Homan RW, Crill WE, Lubozynski MF, Rosenthal NP, Mayersdorf A. (1985) Comparison of carbamazepine, phenobarbital, phenytoin, and primidone in partial and secondarily generalized tonic-clonic seizures. New England Journal of Medicine 313:145-151.
28. Mattson RH, Cramer JA, Collins JF, the Department of Veterans Affairs Epilepsy Cooperative Study No. 264 Group. (1992) A comparison of valproate with carbamazepine for the treatment of complex partial seizures and secondarily generalized tonic-clonic seizures in adults. New England Journal of Medicine 327:765-771.
29. Mattson RH. (1995) Efficacy and adverse effects of established and new antiepileptic drugs. Epilepsia 36(suppl 2):S13-S26.
30. Perucca E. (2003) Current trends in antiepileptic drug therapy. Epilepsia 44(suppl 4):41-47.
31. Smith DB, Mattson RH, Cramer JA, Collins JF, Novelly RA, Craft B, the Veterans Administrative Epilepsy Cooperative Study Group. (1987) Results of a nationwide Veterans Administration Cooperative Study comparing the efficacy and toxicity of carbamazepine, phenobarbital, phenytoin, and primidone. Epilepsia 28(suppl 3):S50-S58.
32. Spinhoven PH, Ormel J, Sloekers PPA, Kempen GIJM, Speckens AEM, Van Hemert AM. (1997) A validation study of the Hospital Anxiety and Depression Scale (HADS) in different groups of Dutch subjects. Psychological Medicine 27:363-370.
33. Tabachnick BG, Fidell LS. (1996) Using multivariate statistics, 3rd ed. New York: HarperCollins.
34. Wiebe S, Eliasziw M, Matijevic S. (2001) Changes in quality of life in epilepsy: how large must they be to be real? Epilepsia 42:113-118.
35. Zaccara G, Cincotta M, Borgheresi A, Balestrieri F. (2004) Adverse motor effects induced by antiepileptic drugs. Epileptic Disorders 6:153-168.
36. Zigmond AS, Snaith RP. (1983) The hospital anxiety and depression scale. Acta Psychiatrica Scandinavica 67:361-370.